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BACKGROUND & AIMS: Inflammatory bowel disease (IBD) patients alter their dietary behaviors to reduce disease-
related symptoms, avoid feared food triggers, and control inflammation. This study aimed to
estimate the prevalence of avoidant/restrictive food intake disorder (ARFID), evaluate risk
factors, and examine the association with risk of malnutrition in patients with IBD.
METHODS: This cross-sectional study recruited adult patients with IBD from an ambulatory clinic. ARFID
risk was measured using the Nine-Item ARFID Screen. Nutritional risk was measured with the
Patient Generated-Subjective Global Assessment. Logistic regression models were used to
evaluate the association between clinical characteristics and a positive ARFID risk screen.
Patient demographics, disease characteristics, and medical history were abstracted from
medical records.
RESULTS: Of the 161 participants (Crohn’s disease, 45.3%; ulcerative colitis, 51.6%; IBD-unclassified,
3.1%), 28 (17%) had a positive ARFID risk score (‡24). Most participants (92%) reported
avoiding 1 or more foods while having active symptoms, and 74% continued to avoid 1 or more
foods even in the absence of symptoms. Active symptoms (odds ratio, 5.35; 95% confidence
interval, 1.91–15.01) and inflammation (odds ratio, 3.31; 95% confidence interval, 1.06–10.29)
were significantly associated with positive ARFID risk. Patients with a positive ARFID risk
screen were significantly more likely to be at risk for malnutrition (60.7% vs 15.8%; P < .01).
aAuthors share co-first authorship.
Abbreviations used in this paper: ARFID, avoidant/restrictive food intake
disorder; BMI, body mass index; CD, Crohn’s disease; CI, confidence in-
terval; CRP, C-reactive protein; DSM-5, Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition; IBD, inflammatory bowel disease; IBS,
irritable bowel syndrome; IOIBD, International Organization for the Study
of Inflammatory Bowel Diseases; IQR, interquartile range; NIAS, Nine Item
Avoidant/Restrictive Food Intake Disorder Screen; OR, odds ratio; PG-
SGA, Scored Patient-Generated Subjective Global Assessment; SCCAI,
Simple Clinical Colitis Activity Index; SD, standard deviation; UC, ulcera-
tive colitis; UCLA, University of California Los Angeles.
© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open
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CONCLUSIONS: Avoidant eating behaviors are common in IBD patients, even when in clinical remission. Pa-
tients who exhibit active symptoms and/or inflammation should be screened for ARFID risk,
with referrals to registered dietitians to help monitor and address disordered eating behaviors
and malnutrition risk.
Keywords: Inflammatory Bowel Disease; Ulcerative Colitis; Crohn’s Disease; Avoidant/Restrictive Food Intake Disorder.
Crohn’s disease (CD) and ulcerative colitis (UC) arechronic inflammatory disorders of the gastroin-
testinal tract that cause symptoms that may be triggered
by dietary intake. This connection leads patients with
inflammatory bowel disease (IBD) to seek dietary solu-
tions for disease management; however, current dietary
recommendations for IBD management are largely based
on low-quality studies with few randomized controlled
trials.1–5 Although the literature in this field is evolving,
the lack of easily accessible, conclusive dietary recom-
mendations have led to patient confusion and, in an
attempt to avoid symptoms and/or control intestinal
inflammation, the development of misapplied, indepen-
dent dietary alterations.6 When patients with IBD take
an independent, unsupervised approach to controlling
their disease through diet, they risk developing restric-
tive eating behaviors that can result in deficient nutri-
tional intake and increased risk of malnutrition.7
In 2013, avoidant/restrictive food intake disorder
(ARFID) was introduced into the Diagnostic and Statis-
tical Manual of Mental Disorders, Fifth Edition (DSM-5)
to broaden the scope of what was previously known as
feeding disorder of infancy and early childhood. The new
ARFID diagnosis is applicable to individuals of any age
whose avoidant/restrictive eating behaviors lead to
insufficient caloric and/or nutrient intake and causes at
least one of the following burdens: significant weight
loss, significant nutritional deficiency, dependence on
nutritional supplements, or marked psychosocial
impairment.8 The DSM-5 describes 3 categories that can
lead to ARFID symptoms: avoidance of many foods based
on their sensory properties (“picky eating”); low appetite
or limited interest in eating; and fear of negative con-
sequences such as choking, vomiting, abdominal pain,
and bloating.8,9 A systematic review of ARFID research
found a wide ranging prevalence of ARFID from 1.5 to
64% among clinical eating disorder populations; how-
ever, most studies were small clinical samples of children
and adolescents.10 In patients with various gastrointes-
tinal disorders, studies have shown that the prevalence
of ARFID is 12%–21%.9,11 Although these studies
demonstrate that ARFID is prevalent in patients with
gastrointestinal disorders, they do not address associa-
tions between ARFID and malnutrition risk.
The association between restrictive eating and
nutritional status is important in patients with IBD
because they are at a higher risk for malnutrition. Studies
have shown that between 16% and 68% of patients with
IBD are malnourished.12,13 Patients with IBD who are
malnourished are at higher risk for nonelective surgeries,
hospitalizations, longer lengths of stay, mortality,14 and
active flares, which impact physical and mental health
and contribute to a poorer quality of life.12
The 3 aims of this study were to estimate the prev-
alence of ARFID risk in adult patients with IBD to identify
risk factors for ARFID and to examine the relationship
between ARFID risk and malnutrition risk. With more
information on the prevalence of restrictive eating and
its association with malnutrition, clinicians can provide
targeted screening, prevention, and treatment for high-
risk patients going forward.
Methods
Participant Recruitment
This cross-sectional study was conducted at the
University of California Los Angeles (UCLA) Center for
Inflammatory Bowel Diseases. Non-consecutive English-
speaking adult patients receiving care at the ambulatory
clinic from October 2019 to March 2020 with a
confirmed diagnosis of IBD were invited to participate in
the study. Exclusion criteria included celiac disease,
anorexia nervosa or bulimia nervosa, unmanaged psy-
chological disorder, alcohol abuse, and pregnancy. The
study was approved by the UCLA Institutional Review
Board.
Data Collection
Participants completed surveys about eating behav-
iors and nutritional status after scheduled clinic visits.
Medical data regarding age, sex, race, ethnicity, substance
use, disease subtype (CD, UC, IBD-unclassified), disease
duration, disease phenotype (location, behavior), medi-
cations (corticosteroids, aminosalicylates, immunomod-
ulators, biologics), and surgical history were abstracted
from the electronic medical records. Laboratory values
(albumin, C-reactive protein [CRP], calprotectin) and
endoscopy findings were abstracted if obtained within 3
months of study participation. The presence of active
IBD-related symptoms was defined as having a Harvey-
Bradshaw Index >4 for patients with CD or a Simple
Clinical Colitis Activity Index (SCCAI) >2 for patients
with UC.15,16 Active inflammation was defined as CRP
5.0 mg/L, calprotectin 250 mg/g, or active inflam-
mation detected on colonoscopy.
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Avoidant/Restrictive Food Intake Disorder Risk
ARFID risk was measured using the validated Nine
Item Avoidant/Restrictive Food Intake Disorder Screen
(NIAS).17 The NIAS is organized into the 3 specific ARFID
domains, each of which is addressed by 3 questions. The
3 domains assess eating restriction due to picky eating,
poor appetite/limited interest in eating, and fear of
negative consequences from eating. Compared with
other instruments that measure picky eating, appetite,
and fear, the ARFID risk screening tool has high internal
consistency (Cronbach’s a ¼ 0.90), test-retest reliability
(intraclass correlation coefficient, 0.65; 95% confidence
interval [CI], 0.56–0.72), and convergent/discriminant
validity for adults aged 18–65.17 Questions are based on
a 6-point Likert scale. Zero indicates “strongly disagree”
and 5 indicates “strongly agree” for a total ARFID risk
score of 0–45. A total threshold of 24 was used to
identify patients at ARFID risk based on previous
research demonstrating good sensitivity (0.74) and
specificity (0.84) for identifying a positive ARFID diag-
nosis.18 Additional survey questions asked about food
groups avoided during a flare and during remission.
Assessment of Nutritional Status
Malnutrition risk was measured using an adapted
version of the validated Scored Patient-Generated Sub-
jective Global Assessment Short Form (PG-SGA).19 The
PG-SGA is based on self-reported criteria and has been
used to evaluate the nutritional risk of malnutrition in
patients with IBD.12 The PG-SGA has 4 sections covering
recent weight change, changes in food intake, symptoms
with possible nutrition impact, and activities and func-
tions. The overall PG-SGA score ranges from 0 (low
malnutrition risk) to 36 (high malnutrition risk).19
Gabrielson et al20 found that a cutoff score of 6 had
high sensitivity (0.938) and specificity (0.776) and was
optimal for capturing patients with confirmed malnutri-
tion. In the third section of the PG-SGA, participants
selected symptoms that subjectively kept them from
eating their normal amount during the preceding 2
weeks. IBD-related symptoms reviewed included lack of
appetite, vomiting, nausea, diarrhea, constipation, smells
bother me, early satiety, fatigue, and pain.
Statistical Analysis
Categorical variables were compared using the c2 or
Fisher exact test. Continuous variables were tested for
normal distribution using the Shapiro-Wilk test. Para-
metric data were summarized as means ( standard
deviation [SD]) or percentages, and non-parametric data
were summarized as medians with interquartile range
(IQR). To test for significant differences between ARFID
domains and ARFID risk score across clinical character-
istics (eg, sex, IBD type, body mass index [BMI], active
symptoms) and eating behaviors (dietary choice and
food avoidance during or in absence of active symp-
toms), the Kruskal-Wallis test was performed. Logistic
regression models were used to evaluate associations
between clinical characteristics and a positive ARFID risk
score 24. Covariates were determined a priori on the
basis of factors thought to influence ARFID risk. Because
of collinearity between active symptoms and inflamma-
tion, regression models evaluated these 2 variables
separately. This also enabled evaluation of the indepen-
dent association between these factors and ARFID risk.
Results were considered statistically significant when P
< .05. Statistical analyses were performed using SPSS
26.0 (SPSS Inc, Cary, NC) and Python 3.8.
Results
Participant Demographics
The ARFID risk questions were completed by 162
patients, and data were abstracted from their electronic
medical records. One patient later withdrew consent and
was excluded from the final analysis. Of the 161
remaining participants, 73 (45.3%) had CD, 83 (51.6%)
had UC, and 5 (3.1%) had IBD-unclassified. Eighty-eight
participants (54.7%) were female, and 73 (45.3%) were
male. The average age of participants was 41.1 years
(mean, 41; SD, 15.5). The majority of participants were
white (n ¼ 114, 70.8%), 6 (3.7%) were black, and 3
(1.9%) were Asian. Ethnically, 14 (8.7%) were identified
as Hispanic. The mean duration of IBD diagnosis was
13.0 years (SD, 11.6). The majority of patients had no
symptoms (n ¼ 110, 68.3%), 11 patients (6.8%) had
recent symptoms within 60 days, and 40 patients
(24.8%) had active symptoms. Fifty-four percent of
participants had a BMI in the normal range, 5.6% were
underweight, and 40.4% were overweight/obese (mean,
What You Need to Know
Background
Patients with IBD often alter their dietary intake.
Malnutrition is prevalent in the IBD population and
is associated with poorer physical health, mental
health, and quality of life.
Findings
Avoidant/restrictive eating behaviors are common in
patients with IBD. Active gastrointestinal symptoms
and intestinal inflammation contribute to ARFID risk.
ARFID risk is associated with malnutrition risk.
Implications for patient care
Among patients with IBD who exhibit active
gastrointestinal symptoms and/or inflammation,
clinicians should consider screening for ARFID.
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24.7 kg/m2; SD, 4.6 kg/m2). BMI did not differ between
IBD types (Kruskal-Wallis H: 2.395; P ¼ .302) (Table 1).
Avoidant/Restrictive Eating Behaviors
Almost all participants (92%) reported avoiding 1 or
more foods whenever having active symptoms, and most
(74%) continued to avoid 1 or more foods even in the
absence of symptoms. Avoidance of diverse food groups
(ie, lactose containing foods, spicy foods, alcohol, wheat
products, deep fried/fatty foods, and caffeine) was
widely prevalent, regardless of symptoms activity;
however, avoidance was significantly higher in each food
group during episodes of active symptoms (Figure 1). A
positive ARFID risk score (24) was present in 17% of
participants. Of the 3 domains assessed by the ARFID
risk screener, fear of negative consequences scored the
highest with a median score of 5 (IQR, 3–9), followed by
picky eating (median, 4; IQR, 2–7), and poor appetite
(median, 3; IQR, 0–6).
Risk Factors
In univariable logistic regression models, active
symptoms (odds ratio [OR], 4.48; 95% CI, 1.89–10.61),
active inflammation (OR, 3.35; 95% CI, 1.28–8.71),
extraintestinal manifestations (OR, 3.40; 95% CI,
1.02–11.3), and recent corticosteroid use (OR, 0.43; 95%
CI, 0.18–0.99) were associated with positive ARFID risk
(Table 2Q5 , Supplementary Table 1). CD behavior or loca-
tion was not associated with ARFID risk. After adjust-
ment for potential confounders, only active symptoms
(OR, 5.35; 95% CI, 1.91–15.01) and inflammation (OR,
3.31; 95% CI, 1.06–10.29) remained significantly asso-
ciated with positive ARFID risk.
Forty-six percent of participants reported 1 or more
symptoms that subjectively prevented them from eating
their normal amount over the preceding 2 weeks. The
most frequently reported problems were fatigue (17%),
lack of appetite (16%), diarrhea (16%), pain (15%),
early satiety (14%), and nausea (13%). Participants who
responded affirmatively to symptoms of lack of appetite
and fullness were significantly more likely to have an
ARFID risk score of 24 or greater compared with those
who did not report those symptoms (lack of appetite and
ARFID risk, 57%; P  .001; fullness and ARFID risk, 56%,
P  .001, respectively). Age, sex, race/ethnicity, BMI, IBD
type, disease duration, recent biologic or immunomod-
ulator use, IBD-related surgery, and alcohol, tobacco, or
drug use were not found to be associated with positive
ARFID risk (Table 2, Supplementary Table 1).
Malnutrition Risk
The PG-SGA questionnaire was completed by 133
participants (83%). Twenty-nine percent of participants
scored 6 (threshold for malnutrition risk). Patients
Table 1. Participant Characteristics (n ¼ 161)
Characteristic N (%)














Crohn’s disease 73 (45.3)
Ulcerative colitis 83 (51.6)
IBD-U 5 (3.1)
Disease duration, mean, mo (SD) 13 (11.6)




Upper gastrointestinal involvement 1 (1.4)




Perianal disease (n ¼ 73)a 25 (15.5)
Two or more EIM 13 (8.1)
Symptoms activityb
None 110 (68.3)
Recent symptoms within 60 days 11 (6.8)








Small bowel resection 15 (9.3)
Colectomy 14 (8.7)





CD, Crohn’s disease; EIM, extraintestinal manifestations; IBD, inflammatory
bowel disease; IBD-U, inflammatory bowel disease-unclassified; SD, standard
deviation.
aOnly calculated for patients with Crohn’s disease.
bActive IBD-related symptoms were defined as Harvey-Bradshaw Index score
>4 for patients with Crohn’s disease or Simple Clinical Colitis Index score >2
for patients with ulcerative colitis. Patients with colectomy and ileal pouch-anal
anastomosis in this study population were asymptomatic.
cn ¼ 156 (5 without response).
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with a positive ARFID risk screen were significantly
more likely to be at risk for malnutrition (60.7% vs
15.8%; P < .01). There was otherwise no difference in
mean serum albumin concentrations (4.1 vs 4.3; P ¼ .60)
when comparing those with versus without a positive
ARFID risk screen. There was a higher proportion of
patients with low BMI who had a high risk of malnutri-
tion (40.0% vs 22.5%; P ¼ .38), although this was not
statistically significant.
Discussion
In a large tertiary-care medical center, we found that
17% of patients with IBD were at risk for ARFID.
Although most participants consciously avoided foods
when actively having symptoms, a large majority (74%)
also avoided foods when in remission. Participants with
active symptoms and inflammation were significantly
more likely to screen positive for ARFID risk, and par-
ticipants who screened positive for ARFID risk were
significantly more likely to be at risk for malnutrition.
ARFID is associated with co-occurring anxiety disor-
ders, gastrointestinal complications, and malnutrition,
and a timely diagnosis can direct treatment and prevent
nutritional and psychological complications.21 Previous
cross-sectional studies in the IBD population have found
that 49%–90% of patients avoid or restrict foods.6,22
Food avoidance is also common among those with inac-
tive disease.23 Among individuals in the general popu-
lation with gastrointestinal disorders, ARFID risk has
been reported between 12% and 21%.9,11 This avoid-
ance is likely due to patients’ beliefs that certain foods
exacerbate IBD symptoms.24 Previous research has
shown that IBD symptoms of pain, cramping, and
diarrhea adversely impact dietary intake, with patients
avoiding more foods during active disease than in
remission.22 We similarly found a higher proportion of
participants avoiding specified food groups while expe-
riencing active gastrointestinal symptoms than during
times without symptoms. Nonetheless, because of the
generally high prevalence of concurrent irritable bowel
syndrome (IBS) in patients with IBD and poor concor-
dance between symptoms and inflammation, we evalu-
ated the latter 2 factors separately in regression
models.25 The consistent association of active symptoms
and inflammation with a positive ARFID risk screen
highlights that both indicators are important contribu-
tors to ARFID risk in the IBD population and that the
presence of either should alert the clinician to consider
screening for ARFID. This relationship between active
symptoms/inflammation and ARFID risk also calls into
question the durability of ARFID behaviors beyond
symptom activity and inflammation, particularly after
effective medical treatment.
Because of the prevalence of malnutrition in the IBD
population12,13 and the self-reported evidence that pa-
tients with IBD avoid or restrict foods in their diets,6,21
this study investigated the relevance of ARFID in the
IBD population and its association with malnutrition risk.
Because malnutrition is challenging to measure, this
study investigated multiple markers of malnutrition risk
including weight and PG-SGA score. The prevalence of
malnutrition risk in this study (29%) aligns with previ-
ously reported rates of 16%–68%.10,11
The potential role of diet in the management of IBD is
a very commonly asked question among patients with
IBD. Although the majority of this study’s participants
demonstrated food avoidance, there is limited evidence
supporting the avoidance of specific foods to prevent or
Figure 1. Avoidance of
food groups according to
presence or absence of
active symptoms. *P < .05;
**P < .001.
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treat IBD flares. In a review of existing research into food
and inflammation, the International Organization for the
Study of IBD (IOIBD) was only able to make recom-
mendations based on low-level evidence or expert
consensus.1 The strongest recommendation was the
avoidance of trans fats, a dietary recommendation that is
also applicable to the healthy general public. The IOIBD
also recommended a reduction in maltodextrins, carra-
geenans, carboxymethylcellulose, polysorbate-80, tita-
nium dioxide, and other nano particles. For patients with
UC, the IOIBD found limited evidence to support a
reduced intake of red/processed meats and myristic acid
(palm oil, coconut oil, dairy fats). This body of research
continues to evolve rapidly, with recent studies demon-
strating benefit with a Crohn’s disease exclusion diet,3
specific carbohydrate diet,4 and Mediterranean diet.5
None of the research or recommendations support the
pervasive food avoidance captured in our study.
Considering this predominant food avoidance, the
European Society for Clinical Nutrition and Metabolism
recommends that patients with IBD in remission un-
dergo counseling by a dietitian to improve nutritional
therapy and avoid malnutrition and nutrition-related
disorders.14 Furthermore, the American Gastroentero-
logical Association specifies that dietitians should
monitor any dietary restrictions to ensure the provision
of nutritional adequacy.26 Our findings that the majority
of patients with IBD avoid 1 or more foods and that
ARFID risk is associated with malnutrition risk further
emphasize the need for dietitians in the care of patients
with IBD.
There were several limitations in this study. First, the
modest sample size may have contributed to inadequate
power to detect the association of different factors (eg,
IBD phenotype, extraintestinal manifestations, biologic
use, smoking) and ARFID risk. Nonetheless, the sample
size was adequate to detect stronger drivers of ARFID
risk such as active symptoms and inflammation. Second,
this study did not clinically confirm an ARFID diagnosis.
Instead, it implemented the NIAS, which has high internal
Table 2. Risk Factors of Avoidant/Restrictive Food Intake Disorder
Characteristic OR (95% CI) P value aOR (95% CI)a P value
Age (y)
18–40 Reference Reference
40–60 1.26 (0.50–3.13) .62 1.75 (0.54–5.65) .35
>60 0.62 (0.16–2.32) .48 1.10 (0.20–5.92) .91
Female 1.35 (0.59–3.10) .48 0.82 (0.28–2.38) .72
White 0.96 (0.39–2.37) .94 0.49 (0.15–1.66) .25
Hispanic 1.33 (0.35–5.12) .68 1.54 (0.32–7.44) .59
Body mass index
Normal Reference Reference
Underweight 1.09 (0.21–5.65) .91 2.78 (0.34–22.49) .34
Overweight 0.64 (0.23–1.76) .39 0.56 (0.15–2.11) .39
Obese 1.25 (0.36–4.30) .72 1.07 (0.22–5.20) .93
IBD type
Crohn’s disease Reference Reference
Ulcerative colitis 1.21 (0.53–2.77) .64 1.40 (0.53–3.68) .50
Disease duration, mo 1.00 (0.96–1.03) .83 1.00 (0.96–1.05) .93
EIM (2) 3.40 (1.02–11.3) <.05 4.96 (0.88–27.77) .07
Recent corticosteroid use 0.43 (0.18–0.99) <.05 0.46 (0.15–1.41) .17
Recent immunomodulator use 0.55 (0.22–1.39) .21 0.35 (0.08–1.49) .15
Recent biologic use 1.74 (0.76–4.02) .19 2.70 (0.80–9.10) .11
Active symptomsb 4.48 (1.89–10.61) <.01 5.35 (1.91–15.01) <.01
IBD-related surgery 1.27 (0.63–2.56) .50 1.83 (0.67–4.98) .24
Tobacco use 0.40 (0.04–37.9) .31 0.40 (0.04–3.88) .43
Drug use 0.81 (0.25–2.66) .73 0.73 (0.16–3.26) .68
Alcohol use 1.62 (0.70–3.77) .27 1.51 (0.50–4.58) .47
aOR, adjusted odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease-unclassified; OR, odds ratio.
aMultivariable models adjusted for the variables listed in the table.
bActive IBD-related symptoms were defined as Harvey-Bradshaw Index score >4 for patients with Crohn’s disease or Simple Clinical Colitis Index score >2 for
patients with ulcerative colitis. Patients with colectomy and ileal pouch-anal anastomosis in this study population were asymptomatic.
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consistency, test-retest reliability, and convergent/
discriminant validity in addition to a validated cutoff
score with good sensitivity and specificity.17,18 We could
therefore only provide an assessment of ARFID risk
rather than diagnosis. Finally, because of the cross-
sectional study design, we could not determine causal-
ity, onset, or duration of ARFID risk before data collec-
tion; however, the identified associations provide
direction for future controlled, prospective studies.
In conclusion, this study establishes that avoidant/
restrictive eating behaviors are common among patients
with IBD even when in clinical remission and are asso-
ciated with malnutrition risk. With this knowledge, pa-
tients with IBD who exhibit active symptoms and/or
inflammation should be screened for ARFID risk. Regular
ARFID screening of patients with IBD and subsequent
referrals to registered dietitians would help direct
appropriate dietary interventions for disease and
symptom management and could help identify early
malnutrition risk, leading to earlier intervention and
improved clinical outcomes. Future longitudinal studies
that investigate the impact of important etiologic factors
(eg, cultural practices, IBS overlap, stress, anxiety, life-
style, effective medical therapy) on ARFID risk would
further improve strategies to prevent or reduce the risk
of ARFID and malnutrition in patients with IBD.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2021.08.009.
References
1. Levine A, Rhodes JM, Lindsay JO, et al. Dietary guidance from
the International Organization for the Study of Inflammatory
Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:1381–1392.
2. Limketkai BN, Iheozor-Ejiofor Z, Gjuladin-Hellon T, et al. Dietary
interventions for induction and maintenance of remission in in-
flammatory bowel disease. Cochrane Database Syst Rev 2019;
2:CD012839.
3. Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet
plus partial enteral nutrition induces sustained remission in a
randomized controlled trial. Gastroenterology 2019;
157:440–450.e8.
4. Suskind DL, Lee D, Kim YM, et al. The specific carbohydrate diet
and diet modification as induction therapy for pediatric Crohn’s
disease: a randomized diet-controlled trial. Nutrients 2020;
12:3749.
5. Lewis JD, Sandler R, Brotherton C, et al. A randomized trial
comparing the specific carbohydrate diet to a Mediterranean
diet in adults with Crohn’s disease. Gastroenterology 2021;
S0016-5085(21):03069-9.
6. Limdi JK, Aggarwal D, McLaughlin JT. Dietary practices and
beliefs in patients with inflammatory bowel disease. Inflamm
Bowel Dis 2016;22:164–170.
7. Vidarsdottir JB, Johannsdottir SE, Thorsdottir I, et al. A cross-
sectional study on nutrient intake and -status in inflammatory
bowel disease patients. Nutr J 2016;15:1–6.
8. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th ed. Washington, DC: American
Psychiatric Pub, 2013.
9. Harer K, Jagielski C, Riehl M, et al. Avoidant/restrictive food
intake disorder among adult gastroenterology behavioral health
patients: demographic and clinical characteristics. Gastroen-
terology 2019;156:S-53.
10. Bourne L, Bryant-Waugh R, Cook J. Avoidant/restrictive food
intake disorder: a systematic scoping review of the current
literature. Psychiatry Res 2020;288:112961–112961.
11. Zia JK, Riddle M, DeCou CR. Prevalence of eating disorders,
especially DSM-5’s avoidant restrictive food intake disorder, in
patients with functional gastrointestinal disorders: a cross-
sectional online survey. Gastroenterology 2017;152:S715–S716.
12. Pulley J, Todd A, Flatley C, et al. Malnutrition and quality of life
among adult inflammatory bowel disease patients. JGH Open
2020;4:454–460.
13. Mijac DD, Jankovic GLJ, Jorga J, et al. Nutritional status in
patients with active inflammatory bowel disease: prevalence of
Table 3. Comparison of Avoidant/Restrictive Food Intake Disorder Risk Score by Domain and Symptoms
Characteristic Negative ARFID risk screen Positive ARFID risk screen P value
Picky eating domain, median score (IQR) 3.0 (2.0–6.0) 8.0 (6.0–10.0) <.01
Poor appetite domain, median score (IQR) 2.0 (0.0–4.0) 10.0 (7.0–12.0) <.01
Fear of negative consequences domain, median score (IQR) 4.0 (2.0–7.0) 12.0 (9.0–14.0) <.01
Symptoms activitya <.01
None 97 (72.9) 13 (46.4)
Recent symptoms within 60 days 11 (8.3) 0 (0)
Active symptoms 25 (18.8) 15 (53.6)
Avoids foods during flareb 121 (91.0) 27 (96.4) .56
Avoids food in absence of flareb 96 (72.2) 23 (82.1) .39
ARFID, avoidant/restrictive food intake disorder; IQR, interquartile range.
aActive inflammatory bowel disease–related symptoms were defined as Harvey-Bradshaw Index score >4 for patients with Crohn’s disease or Simple Clinical
Colitis Index score >2 for patients with ulcerative colitis. Patients with colectomy and ileal pouch-anal anastomosis in this study population were asymptomatic.
bSelf-reported historical flare.
FLA 5.6.0 DTD  YJCGH58041_proof  31 August 2021  2:31 pm  ce CLR





















































































































malnutrition and methods for routine nutritional assessment. Eur
J Intern Med 2010;21:315–319.
14. ForbesA,EscherJ,HébuterneX.ESPENguideline:clinicalnutrition
in inflammatory bowel disease. Clin Nutr 2017;36:321–347.
15. Best WR. Predicting the Crohn’s disease activity index from the
Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304–310.
16. Walmsley RS, Ayres RCS, Pounder RE, et al. A simple clinical
colitis activity index. Gut 1998;43:29–32.
17. Zickgraf HF, Ellis JM. Initial validation of the Nine Item Avoidant/
Restrictive Food Intake Disorder Screen (NIAS): a measure of
three restrictive eating patterns. Appetite 2018;123:32–42.
18. Ellis J, Zickgraf H, Whited MC, et al. Establishing clinical cutoffs
for the screening of avoidant/restrictive food intake disorder.
Ann Behav Med 2017;51(s1):S1198–S1199.
19. Jager-Wittenaar H, Ottery FD. Assessing nutritional status in
cancer: role of the Patient-Generated Subjective Global
Assessment. Curr Opin Clin Nutr Metab Care 2017;20.
20. Gabrielson DK, Scaffidi D, Leung E, et al. Use of an abridged
Scored Patient-Generated Subjective Global Assessment
(abPG-SGA) as a nutritional screening tool for cancer patients in
an outpatient setting. Nutr Cancer 2013;65:234–239.
21. Feillet F, Bocquet A, Briend A, et al. Nutritional risks of ARFID
(avoidant restrictive food intake disorders) and related behavior.
Arch Pediatr 2019;26:437–441.
22. Marsh A, Kinneally J, Robertson T, et al. Food avoidance in
outpatients with inflammatory bowel disease: who, what and
why. Clin Nutr ESPEN 2019;31:10–16.
23. Crooks B, McLaughlin J, Matsuoka K, et al. The dietary prac-
tices and beliefs of people living with inactive ulcerative colitis.
Eur J Gastroenterol Hepatol 2021;33:372–379.
24. Cohen AB, Lee D, Long MD. Dietary patterns and self-reported
associations of diet with symptoms of inflammatory bowel dis-
ease. Dig Dis Sci 2013;58:1322–1328.
25. Strid H. Prevalence of IBS-type symptoms in IBD. Lancet
Gastroenterol Hepatol 2020;12:1029–1031.
26. Colombel J, Shin A, Gibson PR. AGA clinical practice update on
functional gastrointestinal symptoms in patients with inflam-
matory bowel disease: expert review. Clin Gastroenterol Hepatol
2019;17:380–390.e1.
Reprint requests
Address requests for reprints to: Berkeley N. Limketkai, MD, PhD, 100 UCLA
Medical Plaza, Suite 345, Los Angeles, California 90095. e-mail: berkeley.
limketkai@gmail.com; fax: xxx. Q2Q3
Acknowledgments Q6
The authors appreciate the contributions of Anastasia Amundson, Lindsay
Hewitt, Claire Grover, Michele Shi, Arjun Sharma, Nicolette Canlian, and Freida
Raj in patient recruitment and data entry.
CRediT Authorship Contributions
Emily Yelencich (Conceptualization: Equal; Data curation: Equal; Formal
analysis: Lead; Investigation: Equal; Methodology: Equal; Writing – original
draft: Lead)
Emily Truong (Conceptualization: Equal; Data curation: Supporting;
Investigation: Lead; Methodology: Equal; Writing – review & editing:
Supporting)
Adrianne M. Widaman (Formal analysis: Supporting; Writing – original draft:
Supporting; Writing – review & editing: Supporting)
Giselle Pignotti (Writing – original draft: Supporting; Writing – review &
editing: Supporting)
Liu Yang (Data curation: Equal; Formal analysis: Equal; Methodology:
Supporting; Writing – review & editing: Supporting)
Yejoo Jeon (Investigation: Supporting; Methodology: Supporting)
Andrew T. Weber (Investigation: Supporting; Methodology: Supporting;
Writing – review & editing: Supporting)
Rishabh Shah (Investigation: Supporting; Methodology: Supporting;
Writing – review & editing: Supporting)
Janelle Smith (Methodology: Supporting; Writing – review & editing:
Supporting)
Jenny S. Sauk (Investigation: Supporting; Methodology: Supporting;
Writing – review & editing: Supporting)
Berkeley N. Limketkai (Conceptualization: Equal; Data curation: Equal;
Formal analysis: Equal; Investigation: Lead; Methodology: Equal; Project
administration: Lead; Writing – original draft: Supporting; Writing – review &
editing: Supporting)
Conflicts of interest
Q4The authors disclose no conflicts.
FLA 5.6.0 DTD  YJCGH58041_proof  31 August 2021  2:31 pm  ce CLR





















































































































Supplementary Table 1. Risk Factors of Avoidant/Restrictive Food Intake Disorder
Characteristic OR (95% CI) P value aOR (95% CI)a P value
Age (y)
18–40 Reference Reference
40–60 1.26 (0.50–3.13) .62 1.35 (0.38–4.82) .64
>60 0.62 (0.16–2.32) .48 0.27 (0.03–2.82) .28
Female 1.35 (0.59–3.10) .48 1.32 (0.43–4.05) .62
White 0.96 (0.39–2.37) .94 0.66 (0.18–2.45) .54
Hispanic 1.33 (0.35–5.12) .68 1.32 (0.24–7.13) .75
Body mass index
Normal Reference Reference
Underweight 1.09 (0.21–5.65) .91 1.39 (0.19–10.65) .75
Overweight 0.64 (0.23–1.76) .39 0.79 (0.19–3.36) .75
Obese 1.25 (0.36–4.30) .72 0.71 (0.11–4.46) .71
IBD type
Crohn’s disease Reference Reference
Ulcerative colitis 1.21 (0.53–2.77) .64 1.40 (0.52–3.75) .51
Disease duration, mo 1.00 (0.96–1.03) .83 1.01 (0.96–1.06) .64
EIM (2 or more) 3.40 (1.02–11.3) <.05 2.52 (0.38–16.72) .34
Recent corticosteroid use 0.43 (0.18–0.99) <.05 0.62 (0.20–1.95) .42
Recent immunomodulator use 0.55 (0.22–1.39) .21 0.41 (0.10–1.65) .21
Recent biologic use 1.74 (0.76–4.02) .19 2.42 (0.70–8.33) .16
Active inflammationb 3.35 (1.28–8.71) .01 3.31 (1.06–10.29) .04
IBD-related surgery 1.27 (0.63–2.56) .50 1.24 (0.36–4.32) .73
Tobacco use 0.40 (0.04–37.9) .31 0.20 (0.02–1.86) .16
Drug use 0.81 (0.25–2.66) .73 1.21 (0.25–5.86) .81
Alcohol use 1.62 (0.70–3.77) .27 1.44 (0.47–4.39) .52
aOR, adjusted odds ratio; CI, confidence interval; IBD, inflammatory bowel disease; OR, odds ratio.
aMultivariable models adjusted for the variables listed in the table.
bActive inflammation was defined as C-reactive protein 5.0 mg/L, fecal calprotectin 250 mg/g, or active inflammation detected on lower endoscopy within 3
months of participation.
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